

REMARKS

Claims 1-19 are pending in the application. Claims 1 and 12 are in independent form. Claims 2-11 and claims 13-19 are in dependent form. Claims 1-19 stand rejected. By this Amendment, Applicant has amended claim 12, deleted claims 18 and 19, and added new claims 20 and 21.

In the Office Action, the Examiner rejected claims 12-17 under 35 U.S.C. 112, second paragraph, for failing to particularly point out and distinctly claim the subject matter that Applicant regards as the invention. Specifically, the Examiner stated that claim 12, which is directed to a process for preparing a solid composition, contains no process steps. Applicant respectfully traverses this rejection. Claim 12, as amended in the Amendment submitted on November 29, 2001, reads as follows: "A process for the preparation of a solid composition . . . , which comprises combining the 4-amino-3-substituted-butanoic acid derivative with a humectant for manufacturing a pharmaceutical preparation." Claim 12 therefore relates to a process that contains one process step, which is described clearly in the claim. Therefore, Applicant respectfully requests that the foregoing rejection be withdrawn.

However, in view of the length of claim 12 and the fact that the process step is described at the end of the claim and is not delineated from the preamble by a paragraph break, Applicant has, by the above amendments, reformatted claim 12 to better delineate, visually, the process step from the preamble, and to delete the phrase at the end of the claim that reads, "for manufacturing a pharmaceutical preparation".

The Examiner also rejected claims 1-19 under 35 U.S.C. 103(a) as being obvious to those of skill in the art over U.S. Patent 5,025,035 ("Wallace"), U.S. Patent 5,084,479 ("Woodruff"), European Patent 458,751 ("EP 458,751") or the abstract of Japanese Patent 6,325,022 ("JP 6,325,022"). For the reasons that follow, Applicant respectfully traverses the foregoing rejection and requests that it be withdrawn.

As described on pages 3 and 4 of the specification, 4-amino-3-substituted butanoic acid derivatives such as gabapentin have very poor fluidity and stability. To prepare a small dosage form of gabapentin, a large amount of auxiliaries must be used in the compression molding or granulation of gabapentin. However, many of the auxiliaries tend to react with gabapentin. This invention provides a stabilized solid composition, which is characterized by the combination of a humectant as a stabilizer with a 4-amino-3-substituted butanoic acid derivative to stabilize such derivative. By adding a humectant, the degradation of 4-amino-3-substituted butanoic acid derivative in contact with

auxiliaries can be blocked. Thus, the amount of auxiliaries used can be decreased and a tablet or capsule containing a higher dosage of gabapentin with a smaller size can be prepared.

EP 458751, owned by the Applicant, discloses a delivery system for a cyclic amino acid compound providing reduced bitterness with improved mouthfeel, compressibility and high temperature stability. This reference does not teach or suggest the use of a humectant to stabilize the cyclic amino acid compound.

Wallace and Woodruff refer to long lists of pharmaceutical carriers and excipients that can be used to formulate gabapentin. The excipients and carriers mentioned in this list come from very different categories of substances, with no common property among them being stated except that they are "suitable pharmaceutical carriers". Such lists include, but are not limited to, such substances as gelatin capsules, lactose, sucrose, corn starch, talc, cellulose derivatives, stearic acid, peanut oil, oil of theobroma, sesame oil, agar, isotonic saline, gelatin, alginic acid, magnesium stearate, propylene glycol, glycerin, phosphate buffer solutions and sorbitol, and also include "other compatable substances normally used in pharmaceutical formulations". (See Wallace, col. 2, lines 40-61, and Woodruff, cols. 4, lines 3-16). There is no disclosure or suggestion in Woodruff or Wallace of a stabilized formulation containing a 4-amino-3-substituted butanoic acid derivative and a humectant.

JP 6,325,022 refers to a pharmaceutical formulation containing baclofen and a percutaneous absorption adjuvant, such as a C₆ – C₁₂ alcohol in a propylene glycol solvent, or cyclodextrin, in an ointment base, to improve the solubility of the baclofen and render the composition capable of exhibiting sustained drug effects without gastrointestinal side effects, hallucinations, dependence or other side effects. Propylene glycol is mentioned only as a possible solvent for baclofen in such a formulation. There is no teaching or suggestion of a stabilized pharmaceutical formulation.

None of the citations referred to above teaches or suggests the combination of a humectant with the 4-amino-3-substituted butanoic acid derivative to avoid the degradation of such derivative. Persons of skill in the art would by no means infer the same from these citations and produce stabilized solid compositions of 4-amino-3-substituted butanoic acid derivatives in higher dosages with fewer auxiliaries.

The present invention is directed towards protecting the integrity of the formulation process and the stability of the resulting formulation. The present invention's use of a humectant to block the degradation of the 4-amino-3-substituted butanoic acid derivatives that would otherwise occur in the presence of the auxiliary components of the claimed compositions allows for the production of

smaller, stabilized oral compositions containing a higher concentration of drug. This advantage, which is specific to drugs having the particular chemical formula set forth in claim 1, is quite distinct from, and not predictable from, the formulations of the cited art. EP 458751, while referring to compositions containing active agents that are similar structurally to those referred to in the present invention, do not teach or suggest any method of formulating such agents in small, stabilized compositions containing high concentrations of such agents. They certainly do not teach or suggest the specific invention of using a humectant to block the chemically induced degradation of such agents. EP 458751, in contrast to the present invention, is directed towards reducing bitterness and improving mouthfeel, compressibility and stability at high temperatures.

Applicant respectfully submits that the present invention represents an inventive step over the cited art is underscored by the fact that gabapentin degrades into the corresponding lactam in the presence of water, a fact that teaches, if anything, against the use of a humectant to block such degradation.

In view of the foregoing amendments and remarks, Applicant submits that claims 1 through 21 are in condition for allowance, and respectfully requests that they be allowed to issue.

The Commissioner is authorized to charge any fee required for the above amendments to be entered and to credit any overpayment in connection with this communication to our Deposit Account 23-0455.

Respectfully submitted,




Karen DeBenedictis
Reg. No. 32,977
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-3374
Fax (734) 622-1553

Attachment - Amended claims, Version with Markings to Show Changes Made

"VERSION WITH MARKINGS TO SHOW CHANGES MADE"**IN THE CLAIMS:**

Claim 12 (twice amended). A process for the preparation of a solid composition containing a 4-amino-3-substituted-butanoic acid derivative having the general formula



wherein,

R₁ is a hydrogen atom, a hydroxyl group, a methyl group or an ethyl group;

R₂ is a monovalent group selected from:

a straight or branched alkyl group of 3 - 8 carbon atoms;

a straight or branched alkylene group of 3-8 carbon atoms;

a straight or branched alkyl group of 3 - 8 carbon atoms which is mono- or di-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, an oxo group, a carboxyl group or a carboalkoxy group;

a cycloalkyl group of 3 - 8 carbon atoms;

a cycloalkyl group of 3 - 8 carbon atoms which is mono-, di- or tri-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, an oxo group, a carboxyl group or a carboalkoxy group;

a condensed ring group formed by ortho-fusion of a phenyl ring with a cycloalkyl group of 4 - 8 carbon atoms;

a condensed ring group formed by ortho-fusion of a phenyl ring with a cycloalkyl group of 4 - 8 carbon atoms wherein said phenyl ring is mono-, di- or tri-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, a carboxyl group or a carboalkoxy group;

a condensed ring group formed by ortho-fusion of a phenyl ring with a cycloalkenyl group of 5 - 8 carbon atoms or a cycloalkanediaryl group of 5 - 8 carbon atoms;

a condensed ring group formed by ortho-fusion of a phenyl ring with a cycloalkenyl group of 5 - 8 carbon atoms or a cycloalkanediaryl group of 5 - 8 carbon atoms wherein said phenyl ring is mono-, di- or tri-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, a carboxyl group or a carboalkoxy group;

an alkylcycloalkyl group wherein said cycloalkyl has 3 - 8 carbon atoms and is linked to an alkylene group having 1 - 4 carbon atoms optionally interrupted with -O-, -S- or -SS-;

an alkylcycloalkyl group wherein said cycloalkyl has 3 - 8 carbon atoms, is linked to an alkylene group having 1 - 4 carbon atoms optionally interrupted with -O-, -S- or -SS- and is mono-, di- or tri-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, an oxo group, a carboxyl group or a carboalkoxy group;

a cycloalkyl group of 5 - 8 carbon atoms wherein one of the methylene groups (-CH₂-) is replaced by -O-, -NH-, -S-, -SO- or -S(O)₂-;

a cycloalkyl group of 5 - 8 carbon atoms wherein one of the methylene groups (-CH₂-) is replaced by -O-, -NH-, -S-, -SO- or -S(O)₂-, and one or two of the unsubstituted methylene groups (-CH₂-) are mono- or di-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, an oxo group, a carboxyl group or a carboalkoxy group;

a cycloalkenyl group of 5 - 8 carbon atoms or a cycloalkanediaryl group of 5 - 8 carbon atoms, one of the methylene groups (-CH₂-) in said cycloalkenyl ring or cycloalkanediaryl ring being replaced by -O-, -NH-, =N-, -S-, -SO- or -S(O)₂-;

a cycloalkenyl group of 5 - 8 carbon atoms or a cycloalkanediaryl group of 5 - 8 carbon atoms, one of the methylene groups (-CH₂-) in said cycloalkenyl ring or cycloalkanediaryl ring being replaced by -O-, -NH-, =N-, -S-, -SO- or -S(O)₂-, and one or two of the unsubstituted methylene groups (-CH₂-) being mono- or di-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, an oxo group, a carboxyl group or a carboalkoxy group;

a condensed ring group formed by ortho-fusion of a phenyl ring with a cycloalkyl group of 5 - 8 carbon atoms wherein one of the methylene groups (-CH₂-) is replaced by -O-, -NH-, -S-, -SO- or -S(O)₂-;

a condensed ring group formed by ortho-fusion of a phenyl ring with a cycloalkyl group of 5 - 8 carbon atoms wherein one of the methylene groups (-CH₂-) is replaced by -O-, -NH-, -S-, -SO- or -S(O)₂-, said phenyl group being mono- or di-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, a carboxyl group or a carboalkoxy group;

a condensed ring group formed by ortho-fusion of a phenyl ring with a cycloalkenyl group of 5 - 8 carbon atoms or a cycloalkanediaryl group of 5 - 8 carbon atoms, one of the methylene groups (-CH₂-) in said cycloalkenyl ring or cycloalkanediaryl ring being replaced by -O-, -NH-, =N-, -S-, -SO- or -S(O)₂-;

a condensed ring group formed by ortho-fusion of a phenyl ring with a cycloalkenyl group of 5 - 8 carbon atoms or a cycloalkanediaryl group of 5 - 8 carbon atoms, one of the methylene groups (-CH₂-) in said cycloalkenyl ring or cycloalkanediaryl ring being replaced by -O-, -NH-, =N-, -S-, -SO- or -S(O)₂-, said phenyl ring being mono- or di-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, a carboxyl group or a carboalkoxy group;

an alkylcycloalkyl group wherein said cycloalkyl has 5 - 8 carbon atoms and is linked to an alkylene group having 1 - 4 carbon atoms optionally interrupted with -O-, -S- or -SS-, one of the methylene groups (-CH₂-) in said cycloalkyl ring being replaced by -O-, -NH-, -S-, -SO- or -S(O)₂-;

an alkylcycloalkyl group wherein said cycloalkyl has 5 - 8 carbon atoms and is linked to an alkylene group having 1 - 4 carbon atoms optionally interrupted with -O-, -S- or -SS-, and one of the methylene groups (-CH₂-) in said cycloalkyl ring being replaced by -O-, -NH-, -S-, -SO- or -S(O)₂- and one or two of the unsubstituted methylene groups (-CH₂) being mono-, di- or tri-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl

group, an alkyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, an oxo group, a carboxyl group or a carboalkoxy group;

a phenyl or naphthyl group;

a phenyl group substituted with a methylenedioxy group;

a phenyl or naphthyl group which is mono-, di- or tri-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an amino group, a nitro group, a carboxyl group, a phenoxy group, a phenylmethoxy group, a phenylmethoxy group wherein said phenyl ring is mono-substituted with a halogen atom, trifluoromethyl group, an alkoxy group, an amino group, a nitro group, a carboxyl group or a carboalkoxy group, a cycloalkylmethoxy group having 5 - 8 carbon atoms in the cycloalkyl ring, a cycloalkenylmethoxy group having 5 - 8 carbon atoms in the cycloalkenyl ring, a cycloalkanediarylmethoxy group having 5 - 8 carbon atoms in the cycloalkanediaryl ring, a cycloalkylmethoxy group wherein one of the methylene groups (-CH₂-) in said cycloalkyl ring having 5 - 8 carbon atoms is replaced by -O-, -NH-, -S-, -SO- or -S(O)₂-, a cycloalkenylmethoxy group wherein one of the methylene groups (-CH₂-) in said cycloalkenyl ring having 5 - 8 carbon atoms is replaced by -O-, -NH-, =N-, -S-, -SO- or -S(O)₂-, a cycloalkanediaryl-methoxy group wherein one of the methylene groups (-CH₂-) in said cycloalkanediaryl ring having 5 - 8 carbon atoms is replaced by -O-, -NH-, =N-, -S-, -SO- or -S(O)₂- group, a cycloalkylmethoxy group having 5 - 8 carbon atoms in the cycloalkyl ring wherein said cycloalkyl ring is mono-substituted with a halogen atom, trifluoromethyl group, a hydroxy group, an alkyl group, an alkoxy group, an amino group, a nitro group, a carboxyl group or a carboalkoxy group and one of the methylene groups (-CH₂-) in said cycloalkyl ring is replaced by -O-, -NH-, -S-, -SO- or -S(O)₂-, a cycloalkenylmethoxy group having 5 - 8 carbon atoms in the cycloalkenyl ring wherein said cycloalkenyl ring is mono-substituted with a halogen atom, a trifluoromethyl group, a hydroxy group, an alkyl group, an alkoxy group, an amino group, a nitro group, an oxo group, a carboxyl group or a carboalkoxy group and one of the methylene groups (-CH₂-) in said cycloalkenyl ring is replaced by -O-, -NH-, =N-, -S-, -SO- or -S(O)₂-, or a cycloalkanediarylmethoxy group having 5 - 8 carbon atoms in the cycloalkanediaryl ring wherein said cycloalkanediaryl ring is mono-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an amino group, a

nitro group, an oxo group, a carboxyl group or a carboalkoxy group and one of the methylene groups (-CH₂-) in said cycloalkanediaryl ring is replaced by -O-, -NH-, =N-, -S-, -SO- or -S(O)₂-;

an alkylphenyl group wherein said phenyl group is linked to an alkylene group having 1 - 4 carbon atoms optionally interrupted with -O-, -S- or -SS-;

an alkyl-O-, -S- or -SS-phenyl group wherein said phenyl group is linked to an alkylene group having 1 - 4 carbon atoms via -O-, -S- or -SS-;

an -O-, -S- or -SS-phenyl group;

a diphenylamino group;

an alkylphenyl group wherein said phenyl group is linked to an alkylene group having 1 - 4 carbon atoms optionally interrupted with -O-, -S- or -SS- and mono-, di- or tri-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an amino group, a nitro group or a carboxyl group;

an alkyl-O-, -S- or -SS-phenyl group wherein said phenyl group is linked to an alkylene group having 1 - 4 carbon atoms via -O-, -S- or -SS- and mono-, di- or tri-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an amino group, a nitro group or a carboxyl group;

an -O-, -S- or -SS-phenyl group wherein said phenyl group is mono-, di- or tri-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an amino group, a nitro group or a carboxyl group;

or

R₁ and R₂, together with the carbon atom to which they are attached, may form a divalent group selected from:

a cycloalkylidene group of 5 - 8 carbon atoms;

a cycloalkylidene group of 5 - 8 carbon atoms which is mono-, di-, tri- or tetra-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, a cycloalkyl group, a phenyl group, an amino group, a nitro group or a carboxyl group;

a cycloalkylidene group of 5 - 8 carbon atoms wherein one of the methylene groups (-CH₂-) in said cycloalkyl ring is replaced by -O-, -NH-, -S-, -SO- or -S(O)₂-;

a cycloalkylidene group of 5 - 8 carbon atoms wherein one of the methylene groups (-CH₂-) in said cycloalkyl ring is replaced by -O-, -NH-, -S-, -SO- or -S(O)₂- group and one or more of the unsubstituted methylene groups (-CH₂-) in said cycloalkyl ring are mono-, di-, tri- or tetra-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, an oxo group, a carboxyl group or a carboalkoxy group;

a cycloalkenylidene group of 5 - 8 carbon atoms or a cycloalkanediylidene group of 5 - 8 carbon atoms;

a cycloalkenylidene group of 5 - 8 carbon atoms or a cycloalkanediylidene group of 5 - 8 carbon atoms which is mono-, di-, tri- or tetra-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, a cycloalkyl group, a phenyl group, an amino group, a nitro group, an oxo group, a carboxyl group or a carboalkoxy group;

a cycloalkenylidene group of 5 - 8 carbon atoms or a cycloalkanediylidene group of 5 - 8 carbon atoms wherein one of the methylene groups (-CH₂-) in said cycloalkenyl ring or cycloalkanediyl ring is replaced by -O-, -NH-, =N-, -S-, -SO- or -S(O)₂-;

a cycloalkenylidene group of 5 - 8 carbon atoms or a cycloalkanediylidene group of 5 - 8 carbon atoms wherein one of the methylene groups (-CH₂-) in said cycloalkenyl ring or cycloalkanediyl ring is replaced by -O-, -NH-, =N-, -S-, -SO- or -S(O)₂- group and one or more of the unsubstituted methylene groups (-CH₂-) in said cycloalkenyl ring or cycloalkanediyl ring are mono-, di-, tri- or tetra-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, an oxo group, a carboxyl group or a carboalkoxy group;

a condensed ring group formed by ortho-fusion of a phenyl ring with a cycloalkylidene group of 4 - 8 carbon atoms;

a condensed ring group formed by ortho-fusion of a phenyl ring with a cycloalkylidene group of 4 - 8 carbon atoms, said phenyl ring being mono-, di-, tri- or tetra-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl

group, an alkoxy group, an alkylthio group, an amino group, a nitro group, a carboxyl group or a carboalkoxy group;

a condensed ring group formed by ortho-fusion of a phenyl ring with a cycloalkenylidene group of 5 - 8 carbon atoms or a cycloalkanediencylidene group of 5 - 8 carbon atoms;

a condensed ring group formed by ortho-fusion of a phenyl ring with a cycloalkenylidene group of 5 - 8 carbon atoms or a cycloalkanediencylidene group of 5 - 8 carbon atoms, said phenyl ring being mono- or di-substituted with a halogen atom, a trifluoromethyl group, a hydroxyl group, an alkyl group, an alkoxy group, an alkylthio group, an amino group, a nitro group, a carboxyl group or a carboalkoxy group[,];

[which] wherein said process comprises combining the 4-amino-3-substituted butanoic acid derivative with a humectant [for manufacturing a pharmaceutical preparation].

Claim 20 (new). A stabilized solid composition according to Claim 1, wherein the 4-amino-3-substituted butanoic acid derivative is further combined with an auxiliary agent.

Claim 21 (new). The process as claimed in Claim 12, further comprising adding an auxiliary agent to the composition containing the 3-substituted butanoic acid derivative.